Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Gary R CutterRichard A RudickCarl de MoorCarol M SinghElizabeth FisherThijs KosterFred D LublinJerry S WolinskyHenry McFarlandSteven JacobsonMaria L NaylorPublished in: Multiple sclerosis journal - experimental, translational and clinical (2023)
sNfL levels were reduced within 6 months and remained low at 36 months. Results suggest that the combination of lesion activity and sNfL was a stronger predictor of relapse than either factor alone.
Keyphrases
- multiple sclerosis
- end stage renal disease
- phase iii
- newly diagnosed
- ejection fraction
- phase ii
- white matter
- clinical trial
- double blind
- open label
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- placebo controlled
- disease activity
- systemic lupus erythematosus
- study protocol
- cerebrospinal fluid
- rheumatoid arthritis
- free survival